Numerous preclinical studies demonstrate that changes in gene expression in the brain occur in animal models of depression using exposure to stress, such as social defeat and leaned helplessness, and that repeated administration of antidepressants ameliorates these stress-induced changes in gene expression. These findings suggest that alteration in gene transcription in the central nervous system in response to stress plays an important role in the pathophysiology of depression. Recent advances in epigenetics have led to the realization that chromatin remodeling mediated by histone deacetylase (HDAC) is closely involved in the regulation of gene transcription. In this context, we first review several preclinical studies demonstrating the antidepressant-like efficacy of HDAC inhibitors. We then suggest the efficacy of HDAC inhibitors in treatment-resistant depression based on the mechanism of action of HDAC. Finally, we discuss the possibility of using HDAC inhibitors in patients with treatment-resistant depression.
Introduction
Major depression was ranked first among 10 leading diseases with respect to global disease burden in high-income countries in 2001 as indicated by a systematic analysis of population health data, and it accounted for the third-highest number of disability-adjusted life years (Lopez et al., 2006) . Although different types of antidepressants including selective serotonin reuptake inhibitors (SSRIs), serotonin noradrenaline reuptake inhibitors (SNRIs), bupropion, and mirtazapine, have been developed and used clinically, a certain percentage of patients with depression do not show an adequate response to these newer antidepressants or to tricyclic antidepressants.
Results from the Sequenced Treatment Alternatives to Review Depression (STAR*D) study demonstrated that almost 35% of 3671 patients with nonpsychotic major depressive disorder did not achieve remission, despite undergoing 1 to 4 successive treatment steps during which 6 different types of antidepressants (SSRI, SNRI, tricyclic antidepressant, bupropion, mirtazapine, and monoamine amine oxidase inhibitor) were administered (Rush et al., 2006) . Similarly, the Combining Medications to Enhance Depression Outcomes (CO-MED) study showed that the remission rate of a 12-week combination treatment with the 2 different types of antidepressants including bupropion, mirtazapine, citalopram, and venlafaxine, was approximately 40% among patients with major depression (Rush et al., 2011) . Given the limited efficacy of antidepressants, the use of aripiprazol to augment antidepressant therapy is approved by the U.S. Food and Drug Administration (FDA) for patients with antidepressant-resistant depression. In addition, electroconvulsive treatment is often selected in the treatment of drugresistant depression in Japan. Given that there exists such a large percentage of depressed patients who are drug-resistant, a new class of antidepressants with mechanisms distinct from the regulation of monoaminergic signal transduction is required.
Preclinical studies on the pathophysiology of depression suggest that changes in gene expression, such as brain-derived neurotrophic factor (BDNF) (Duman et al., 1997; Nestler et al., 2002) , glial cell line-derived neurotrophic factor (GDNF) (Hisaoka et al., 2001; Uchida et al., 2011) , and vascular endothelial growth factor (VEGF) (Greene et al., 2009) Abbreviations: HDAC, histone deacetylase; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin noradrenaline reuptake inhibitor; BDNF, Brain-derived neurotrophic factor; GDNF, glial cell line-derived neurotrophic factor; FEGF, vascular endothelial growth factor; VPA, valproic acid; HAT, histone acetyltransferase; SIRT, silent information regulator 2-related protein; NAD, nicotinamide-adenine-dinucleotide; SAHA, suberanilohydroxamic acid; NAc, nucleus accumbens; SB, sodium butyrate; TST, tail suspension test; FST, forced swim test; VLO, ventrolateral 
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